MedTrace Logo

Feasibility Trial for a Right Ventricular Failure Platform Trial

NCT06570473 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-09-18

No results posted yet for this study

Summary

The primary objective of the CRAVE feasibility trial is to assess the feasibility of conducting a larger CRAVE platform trial by performing a randomized trial of 30 participants with pulmonary hypertension and right ventricular dysfunction, comparing empagliflozin or ranolazine plus standard of care to standard of care alone.

Conditions

  • Pulmonary Hypertension
  • Right Ventricular Dysfunction
  • Right Heart Failure

Interventions

DRUG

Empagliflozin

Tablet

DRUG

Ranolazine

Tablet

Sponsors & Collaborators

  • Canadian Heart Function Alliance

    collaborator UNKNOWN

  • Accelerating Clinical Trials Consortium

    collaborator OTHER

  • Ottawa Heart Institute Research Corporation

    collaborator OTHER

  • Team PHenomenal Hope

    collaborator UNKNOWN

  • University of Alberta

    lead OTHER

Principal Investigators

  • Jason Weatherald, MD,MSc,FRCPC · University of Alberta

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-15
Primary Completion
2026-08-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06570473 on ClinicalTrials.gov